
|Articles|November 8, 2004
OIG study on Medicaid drug prices infuriates R.Ph.s
A recent Office of Inspector General study of how much states pay R.Ph.s for Medicaid drugs outrages some industry leaders. "I'm disgusted," said John Coster, VP of the National Association of Chain Drug Stores. "Instead of a real analysis of the program, they restate the obvious, which is that states pay [for Medicaid drugs] differently. With all due respect, it reflects a trend of OIG reports that lack methodological rigor."
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
2
How the Delinking Model Can Drive Transparency, Avoid PBM Manipulation | NCPA 2025
3
Lower Baseline BMI Predicts Weight Loss At 6 Months With Liraglutide
4


























































































































































